Post-Marketing surveillance for HPV infection related serious disease in a cohort of Chinese women who received GARDASIL® and GARDASIL®9 (V503-107)

19/11/2026
19/11/2026
EU PAS number:
EUPAS1000001165
Study
Planned
Study identification

EU PAS number

EUPAS1000001165

Study ID

1000001165

Official title and acronym

Post-Marketing surveillance for HPV infection related serious disease in a cohort of Chinese women who received GARDASIL® and GARDASIL®9 (V503-107)

DARWIN EU® study

No

Study countries

China

Study description

The purpose of this study is to provide longer follow-up and an increased sample size for post-marketing surveillance of high-grade cervical disease among Chinese women. The main objective of the study is to monitor the occurrence of high-grade cervical intraepithelial neoplasia (CIN2/3) in women who received GARDASIL® or GARDASIL®9 and tested negative for human papillomavirus (HPV) and in matched women who did not receive HPV vaccination in Zhejiang Province, China. The study will also monitor CIN2/3 among women vaccinated with GARDASIL® or GARDASIL®9 and provide information on CIN2/3, adenocarcinoma in situ (AIS), and cervical cancer in the general female population in Zhejiang Province, China.

Study status

Planned
Research institutions and networks

Institutions

Merck Sharp & Dohme LLC
United States
First published:
08/07/2025
Institution Pharmaceutical company

Contact details

Clinical Trials Disclosure Merck Sharp & Dohme LLC

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:

Study start date

Planned:

Data analysis start date

Planned:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Merck Sharp & Dohme LLC
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Non-EU RMP only